Corpus Intelligence IC Memo — HUNTINGTON HOSPITAL 2026-04-26 03:50 UTC
IC Memo — HUNTINGTON HOSPITAL
Investment Committee Memorandum | NY | 269 beds | Grade C | EBITDA uplift $35.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HUNTINGTON HOSPITAL

CCN 330045 | SUFFOLK, NY | 269 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HUNTINGTON HOSPITAL is a 269-bed suburban community hospital in SUFFOLK, NY with $479.9M in net patient revenue and a -27.8% operating margin. The hospital serves a payer mix of 46.6% Medicare, 4.7% Medicaid, and 48.7% commercial.

Thesis: Undervalued. Our ML models identify $35.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -27.8% to -20.5% (+736bps).

Net Revenue HCRIS$479.9M
Current EBITDA COMPUTED$-133.5M
Operating Margin COMPUTED-27.8%
Occupancy HCRIS81.0%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS28.3%
Distress Probability ML41.5%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
95
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -27.8% places it below the state median. Among 95 size-comparable peers (134-538 beds), the median margin is -17.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (134-538), prioritizing same-state peers. 95 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HUNTINGTON HOSPITAL (Target)NY269$479.9M-27.8%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
LENOX HILL HOSPITALNY415$1.32B-35.1%
BELLEVUE HOSPITAL CENTERNY527$1.31B-17.6%
STATEN ISLAND UNIVERSITY HOSPINY515$1.23B-34.6%
JACOBI MEDICAL CENTERNY440$1.14B-16.8%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
ROCHESTER GENERAL HOSPITALNY470$1.05B-27.9%
NYC HEALTH+HOSPITAL/KINGS COUNNY381$1.03B-15.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $35.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$10.1M+210bp18mo
Cost to Collect4.5%2.5%$9.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$9.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$5.8M+122bp9mo
Clean Claim Rate88.0%96.0%$307K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$10.1M
Cost to Collect
$9.6M
Denial Rate Reduction
$9.5M
A/R Days Reduction
$5.8M
Clean Claim Rate
$307K
Total EBITDA Uplift$35.3M
Current EBITDA$-133.5M
+ RCM Uplift+$35.3M
Pro Forma EBITDA$-98.2M
Current Margin-27.8%
Pro Forma Margin-20.5%
WC Released (1x)$18.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-205.4M$-527.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-205.4M$-646.7M0.00x-100.0%
Bull Case9.0x11.0x$-184.8M$-596.9M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-184.8M$-705.7M0.00x-100.0%
Bear Case11.0x10.0x$-225.9M$-637.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-225.9M$-774.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 95 hospitals with 134-538 beds
  • Same-state prioritization (n=96)
  • Comp margins: P25=-28.1% / P50=-17.7% / P75=-9.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.